A Novel Plasma-Based Methylation Panel for Upper Gastrointestinal Cancer Early Detection

Area of Science:

• Oncology
• Molecular Diagnostics
• Biomarker Discovery

Background:

• Upper gastrointestinal cancer (UGC) is a leading cause of cancer mortality in China.
• Late-stage diagnosis significantly contributes to low five-year survival rates for UGC.
• There is a critical need for non-invasive, cost-effective early detection methods for UGC.

Purpose of the Study:

• To develop and evaluate a novel plasma-based methylation panel for the early detection of upper gastrointestinal cancer.
• To assess the diagnostic performance of individual and combined methylated biomarkers (ELMO1, ZNF582, TFPI2) in plasma samples.

Main Methods:

• A panel was developed to simultaneously detect methylation of three biomarkers (ELMO1, ZNF582, TFPI2) and an internal control gene in plasma.
• Plasma samples from 186 UGC patients and 190 control subjects were analyzed.
• Quantitative PCR was used to assess biomarker amplification efficiency and methylation levels.

Main Results:

• The methylation panel demonstrated excellent PCR amplification efficiency and reproducibility.
• Significantly higher methylation levels of ELMO1, ZNF582, and TFPI2 were observed in UGC samples compared to controls.
• The combined three-marker panel achieved a sensitivity of 71.0%, specificity of 90.0%, and an AUC of 0.870 for UGC detection.

Conclusions:

• Methylated ELMO1, ZNF582, and TFPI2 are specific biomarkers for upper gastrointestinal cancer.
• The three-methylated gene panel offers a promising non-invasive alternative for early UGC detection.
• This approach could improve patient outcomes by enabling earlier diagnosis and treatment.